Interestingly, both percentages are considerably lower than the approximately 50% loss observed between first- and second-line palliative chemotherapy in metastatic NSCLC (22–25), but comparable to the approximately 30% loss reported after first-line TKI treatment in EGFR+ NSCLC patients, both in the standard arm of the phase 3 FLAURA trial [(32%, Supplementary Table S2 of the respective original publication (26)] as well as in real-world analyses from certified German lung cancer centers, including own data (27–29). The gene discussed is EGFR; the disease is lung cancer.